Helios

Helios — Injectable Clenbuterol and Yohimbine by Dragon Pharma

Helios is Dragon Pharma's injectable formulation combining Clenbuterol and Yohimbine at 5.8mg/ml in a 10ml aqueous vial — the only injectable fat loss blend in the range. Administered subcutaneously, Helios delivers the same beta-2 agonist + alpha-2 antagonist dual mechanism as the oral CYT3 combination, but through a route of administration that enables a specific application unavailable with oral compounds: localised subcutaneous injection near stubborn fat deposits.

Also searched as: Helios injection, injectable Clenbuterol Yohimbine, Helios fat loss Dragon Pharma, subcutaneous fat burner injection.

Why Injectable vs Oral — The Localised Application Rationale

The defining characteristic of Helios is its injectable format, and the specific reason this matters is rarely explained in competitor content:

• When Clenbuterol and Yohimbine are taken orally, they are absorbed through the gastrointestinal tract, enter the portal circulation, pass through the liver and then distribute systemically throughout the body — their concentration in any specific fat depot is determined by blood flow to that area, not by proximity of ingestion
• When Helios is injected subcutaneously directly into or adjacent to a fat deposit, the compounds first encounter the local tissue before entering the bloodstream — theoretically creating a transient elevated local concentration at the injection site before systemic distribution occurs
• The Yohimbine component is particularly relevant here: alpha-2 receptors are more densely expressed in stubborn fat areas (lower abdomen in men, hips and thighs in women). Injecting Yohimbine directly adjacent to these alpha-2-rich deposits provides local alpha-2 receptor blockade at the site before systemic dilution occurs
• Similarly, Clenbuterol's local beta-2 agonism at the injection site stimulates lipolysis in that specific adipose tissue region before systemic distribution
• This is the basis of Helios's "spot reduction" application — a concept that is physiologically impossible with oral compounds (which distribute systemically regardless of where consumed) but theoretically achievable with subcutaneous injection near a specific fat depot

The Scientific Context — What "Spot Reduction" Actually Means

A balanced and honest explanation that competitor content typically omits:

• Traditional "spot reduction" (e.g. abdominal exercises reducing belly fat) is a myth — exercise-driven lipolysis is systemic, not local
• Injectable lipolytic compounds are different: pharmacological agents injected subcutaneously can create genuinely elevated local concentrations in adjacent adipose tissue before systemic absorption. This is the mechanistic basis for mesotherapy in clinical aesthetic medicine — a well-established practice
• The evidence for injectable Clenbuterol + Yohimbine as a practical spot reduction tool in bodybuilding is primarily anecdotal — robust human RCT data on Helios specifically for spot reduction does not exist
• The systemic effects of Helios also occur — all compounds are eventually absorbed systemically, producing the same beta-2 and alpha-2 receptor effects as oral administration. The local effect is additional to, not instead of, the systemic effect

Helios Composition and Mechanism

The combination mirrors the rationale of CYT3's Clenbuterol + Yohimbine component: beta-2 agonism drives fat release from adipocytes while alpha-2 antagonism removes the inhibitory signal in stubborn fat depots. In Helios, this dual mechanism is delivered to the target site via injection rather than orally.

Effects and Benefits

• Localised lipolytic activity at injection site — the primary unique advantage over oral fat loss compounds
• Beta-2 receptor activation (Clenbuterol) driving fatty acid release from local adipocytes
• Alpha-2 receptor blockade (Yohimbine) removing the anti-lipolytic brake in stubborn fat depots
• Systemic fat loss effects from both compounds as they absorb into general circulation
• No hormonal effects — no testosterone suppression, no PCT required

Dosage and Administration

Injection technique is important for Helios — use an insulin syringe (27-29 gauge, short needle) for subcutaneous injection. Pinch the skin and inject at a 45-degree angle into the subcutaneous fat layer, not into muscle. Rotate injection sites to avoid localised irritation. Morning injection before fasted cardio is the most commonly reported protocol — the systemic beta-2 and alpha-2 effects combine with the fasted lipolytic state. At $33 per 10ml vial at 5.8mg/ml, Helios is one of the most cost-effective fat loss products in the range.